Resources for students such as educational tools covering a variety of managed care topics and information on professional opportunities (internships, APPEs, fellowships and residencies) related to managed care pharmacy.

PDTs are evidence-based treatments that use software or virtual tools, and sometimes hardware, to deliver a clinical benefit to patients. They have many known uses, helping Americans identify, treat, and manage illnesses across a wide range of conditions, including post-traumatic stress disorder (PTSD), diabetes management, substance and opioid use disorder, attention-deficit hyperactivity disorder (ADHD), chronic back pain, decreasing eyesight, and more. PDTs are subject to review and authorization by the Food & Drug Administration (FDA) and must be prescribed by a health care provider.

AMCP Supports the Medicaid VBPs for Patients Act

The ECAPS Act will help ensure that Americans can continue to rely on pharmacists for potentially life-saving care to combat a range of diseases. Nearly nine in 10 Americans live within five miles of a pharmacy, and patients increasingly rely on pharmacists as their first point of care.

Read the Journal of Managed Care + Specialty Pharmacy (JMCP) May 2025 Issue

AMCP is your partner in navigating AI’s transformative potential—ensuring patient-centered, ethically sound, and strategically aligned implementation across pharmacy practice and policy.

Key takeaways from AMCP’s recent AI Preconference in Houston, Texas, where leaders in pharmacy, healthcare, technology, and policy gathered for a half-day of deep, engaging discussions at AMCP 2025.

ASAE awarded AMCP the 2025 Gold Circle Award in the Website category. The Gold Circle Awards competition is the premier association marketing, membership, and communications award that recognizes excellence, innovation, and achievement in association/nonprofit marketing, membership, and communications programs.

Retinal diseases in patients with diabetes pose signicant challenges for health care systems. With a high treatment burden and advances in durable therapies, managed care organizations can optimize patient care by addressing coverage barriers that impact timely treatment with anti-VEGF therapies. This roadmap outlines essential points to better retinal disease management and improve treatment for populations of patients with diabetes at high risk for blindness.